Yuya Matsue
Yuya Matsue is an expert in Cardiology at Juntendo University (Japan). As of October 2026, ScienceLeadR ranks Yuya Matsue in the top 1% of experts worldwide for Heart Failure, and in the top 1% of experts in Japan for Sarcopenia. Yuya Matsue has authored 353 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 4 of them ongoing. SLR score: 1,460 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Geriatrics - Nutrition
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 353
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prognostic Impact of a Simple GDMT Score on Clinical Outcomes and Cardiac Reverse Remodelling in Patients with ADHF: Insights from the JROADHF-Next Registry. PMID 42861231 — registries, confidence intervals, heart failure, brain, natriuretic peptide, brain, heart failure, systolic, natriuretic peptides, prognosis | CJC Open | 2026 | 0 |
| Frailty and Bleeding Events in Heart Failure: Insights from the JROADHF-NEXT. PMID 42861219 — anticoagulants, mortality, hemorrhage, heart failure, heart, therapeutics, frailty, prognosis | CJC Open | 2026 | 0 |
| Comparative Prognostic Performance of BMI- and Height-Indexed Muscle Mass in Older Patients With Heart Failure: Insights From FRAGILE-HF. PMID 42816755 — mortality, body mass index, muscles, heart failure, heart, aged, muscle, skeletal, prognosis, sarcopenia | J Am Geriatr Soc | 2026 | 0 |
| Sacubitril/valsartan and cardiac injury/stress and systemic inflammatory biomarkers in acute heart failure: a prespecified secondary analysis of the PREMIER study. PMID 42725483 — valsartan, heart failure, heart, stress, physiological, growth differentiation factor 15, biomarkers, angiotensins, therapeutics | Eur Heart J Cardiovasc Pharmacother | 2026 | 0 |
| Management and Outcomes of Cardiac Sarcoidosis: Insights From the Nationwide MYSTICS Registry. PMID 42717875 — registries, hospitalization, sarcoidosis, heart failure, heart, arrhythmias, cardiac, prognosis | Circ Heart Fail | 2026 | 0 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure NCT07397650 — safety, heart failure, heart, tablets, therapeutics | Phase 4 | Recruiting | 2026 |
| OverTTuRe Characteristics Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis NCT06355934 — quality of life, activities of daily living, multiple chronic conditions, amyloidosis, therapeutics, data analysis, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | N/A | Recruiting | 2023 |
| Early Treatment With a Sodium glucose Co transporter 2 Inhibitor in High risk Patients With Acute Heart Failure NCT05392764 — heart failure, heart, symporters, therapeutics | Phase 3 | Recruiting | 2022 |
| Program of Angiotensin Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER) NCT05164653 — enzyme inhibitors, angiotensin ii, valsartan, administration, oral, receptors, angiotensin, angiotensin-converting enzyme inhibitors, safety, hospitalization, heart failure, pharmaceutical preparations, heart, peptidyl-dipeptidase a, drug combinations, tablets, neprilysin, angiotensins, angiotensin receptor antagonists, enzymes, therapeutics | Phase 4 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map